Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022116 (
ischemia
)
91,303
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
PTPN21
, a cytosolic non-receptor tyrosine phosphatase isolated from human skeletal muscle, was reported to promote neuronal survival. Nevertheless, it is not clear whether
PTPN21
plays a role in hypoxia
ischemia
-induced neuronal injury. A proper understanding of the
PTPN21
mechanism in neuron growth regulation is limited. In this study, we investigated the neuroprotective effects and potential mechanism of
PTPN21
on oxygen glucose deprivation (OGD)-injured PC12 cells. The ischemic stroke model of PC12 cells was made by OGD for 2h, after transfection of the
PTPN21
siRNA and pcDNA 3.1
PTPN21
(+). Cell viability was tested using the MTT and CCK-8 assay. Apoptotic cells were estimated by Annexin V-FITC/PI staining and caspase-3 activity using the Caspase-3 Assay Kit; the
PTPN21
, cdk5, ERK1/2 and p-ERK1/2 levels were estimated by qRT-PCR and Western blot. We found that the
PTPN21
markedly increased cell viability, inhibited apoptosis. We also found that
PTPN21
inhibited caspase-3 activity and down-regulating the Bax/Bcl-2 ratio. Furthermore, the expression of cdk5 protein was up-regulated by
PTPN21
by activating ERK1/2 signaling pathway. Finally, our results showed that cdk5 siRNA or ERK1/2 signaling inhibitor PD98059 attenuated the accelerative effect of pcDNA3.1
PTPN21
(+) on cell proliferation and apoptosis in PC12 cells. In short, it appears that
PTPN21
may protect the PC12 from
ischemia
injury by upregulating cdk5 via ERK1/2 signaling pathway.
...
PMID:PTPN21 protects PC12 cell against oxygen-glucose deprivation by activating cdk5 through ERK1/2 signaling pathway. 2884 27